Vialogy moves to protect IP
Vialogy rose strongly after completing patent filings for its seismic data technology in nine key energy markets.
Vialogy rose strongly after completing patent filings for its seismic data technology in nine key energy markets.
The firm said the filings for QuantumRD , which interprets core seismic data for the oil and gas industry, would protect its intellectual property ahead of expanded use in countries like India.
"Enforceable coverage in specific national markets is essential because the laws of the country where the technology is used have legal precedence over the technology's country of origin," the company said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"The filings cover QuantumRD use in conventional sandstone reservoirs, carbonates and nonconventional shale oil/gas plays for both onshore and offshore use."
The nine countries are Brazil, China, Russia, India, Canada, Mexico, Qatar, Bahrain and Israel.
Vialogy has also made preliminary filings for the technology in the European region, covering 38 countries signed up to the European Patent Convention.
The companies shares were up 5.9% after an hour of trading on Monday.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published